Back to search
Metastatic Hormone-Sensitive Prostate Cance
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Metastatic Hormone-Sensitive Prostate Cance trials may be worth asking aboutClinical trial pipeline · Data from ClinicalTrials.gov
See which Metastatic Hormone-Sensitive Prostate Cance trials may be worth asking aboutNorth America
Europe
Asia-Pacific
Rest of World
Trials may have sites in multiple countries. Filtering shows any trial with at least one site in the selected country.
GUARD-QUANTUM is a prospective, phase II, single-arm, non-randomized, non-blinded, investigator-initiated study. The rationale behind studying this combination…
This study will follow patients with metastatic hormone-sensitive prostate cancer (mHSPC) who receive androgen deprivation therapy (ADT) combined with different…